Stock fact sheet · data as of

Beyond Air, Inc. (XAIR): fair value, margin of safety and Wheel Score

Healthcare · Medical - Devices · United States · Speculative / Distressed

Close2.10
GLS fair value12.111 of 9 models
Margin of safety+83%price below fair value
Wheel Score39No optionscapped: no options
Health4/9Piotroski F-score
Moat0.0/10GLS 10-year score
Market cap$1M58k shares a day
Implied vol.-no listed options
P/E-EPS -46.43
Dividend yieldnone
Beta0.15moves less than the market
Next earnings10 Nov 2026in 25 days

Is XAIR undervalued?

XAIR has a margin of safety of 83%: the stock closed at 2.10 on 16 Oct 2026 against a GLS average fair value of 12.11. 1 of the 1 valuation models that produced a number sit above the price. Our screens treat a discount this large as a strong starting point for a cash-secured put, not as a verdict - the fair value is a model output, and a wide gap can mean the models are missing something the market knows.

Only 1 of the nine models produced a value (DCF); the others need a dividend, positive free cash flow or positive book value the company does not have yet, so the average rests on a narrow base.

The nightly engine files XAIR under Speculative / Distressed - negative earnings or a Piotroski score of 3 or less - which caps its Wheel Score at 45 and keeps it out of the Sunday Scan.

Nine valuation models for XAIR

Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.

ModelValuevs priceWhat it measures
DCF12.11+477%Present value of the projected free cash flows, discounted at the cost of capital
Graham Number--The most a defensive investor pays for the earnings and book value per share; no value tonight
Graham Growth--Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields; no value tonight
Lynch--EPS × the earnings growth rate (PEG of 1), growth capped at 25%; no value tonight
GLS Growth--EPS compounded ten years at the blended growth rate, discounted back at 15% a year; no value tonight
10 Cap--Owner's earnings (operating cash flow less maintenance capex) capitalised at 10%; no value tonight
Payback Time--Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight
DDM--Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight
EPV--Earnings power value: current EPS capitalised at 9% with no growth; no value tonight
Zombie (liquidation)-6.95-431%Current assets less all liabilities, per share: the balance-sheet floor. Not in the average
Wall St target10.00+376%Analysts' average 12-month price target. Not in the average

Quality and financial health

Financial health is weak: XAIR passes 4 of the nine Piotroski tests. Our screens drop the stock at the health rule; a low score is often the reason a stock looks cheap on the valuation models. The GLS Moat score is low at 0.0 out of 10, which says the ten-year record of revenue, earnings, margins and returns on capital has been inconsistent - growth and shocks rather than steady compounding.

Returns on capital are thin or negative - ROIC -112.7%, ROE -542.8%, ROA -94.0% - with debt at 3.82 times equity and negative free cash flow. Debt of 3.82 times equity is on the high side for the sector and is worth checking against the cash flow before treating the stock as a long-term hold.

Beyond Air, Inc. pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain. Revenue comes mainly from Business 100% (quarter Q1 FY2027).

Institutional ownership scores 2/10, insider activity 10/10 and Congressional trading 5/10 on the GLS smart-money scales.

Piotroski F-score4 / 9ROIC-112.7%
GLS Moat0.0 / 10ROE-542.8%
Debt / equity3.82ROA-94.0%
Free-cash-flow yield-1470.6%Payout ratio0%
Institutions2 / 10Insiders · Congress10 · 5 / 10

Wheel Score 39: No options

XAIR has no listed options in the nightly snapshot, so there is nothing to sell and the stock cannot be wheeled however good the business; the Wheel Score is capped at 39 and shown as "No options" (39 here). The valuation and quality numbers still apply to owning the shares outright.

Volume runs at 58k shares a day on a market cap of $1M, with a beta of 0.15 - a low beta, so day-to-day moves are smaller than the market's; the Stability part of the Wheel Score gives that 6 of 20.

PartPointsFrom
Value25 / 2583% margin of safety
Health9 / 20Piotroski 4/9
Moat0 / 15moat 0.0/10
Premium0 / 20no option data
Stability6 / 2058k shares/day, $1M cap, beta 0.15

The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.

Upcoming events

The next earnings report is due on 10 Nov 2026, 25 days away; a 30-45-day put sold today would expire after it, which is worth weighing against the premium.

Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.

Similar stocks in Medical - Devices

The 12 companies below are the closest to Beyond Air, Inc. by market cap within the Medical - Devices industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.

StockCloseFair valueMoSWheelMkt cap
ESMC
Escalon Medical Corp.
0.180032.38+99%39No options$1M
TNON
Tenon Medical, Inc.
2.82--30No options$1M
PFSA
Profusa, Inc. Common Stock
1.28--30No options$1M
AMIX
Autonomix Medical, Inc.
2.9318.46+84%38No options$2M
NXL
Nexalin Technology, Inc.
2.45--22No options$2M
VVOS
Vivos Therapeutics, Inc.
0.1340--27No options$2M
VNRX
VolitionRX Ltd
0.1790--39Weak$2M
BJDX
Bluejay Diagnostics, Inc.
0.779310.79+93%39No options$806K
POAS
Phaos Technology Holdings (Caym
2.43--14No options$2M
ADGM
Adagio Medical Holdings, Inc.
0.1030--30No options$2M
ICCM
IceCure Medical Ltd
1.04--32No options$2M
CYDX
CYduct Diagnostics, Inc.
0.50000.0180-2681%20No options$3M

⚖ Compare XAIR with 7 of them   All Healthcare stocks →

Screen the whole market the same way

A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.

Start free See the Sunday Scan

Questions about XAIR

Is XAIR undervalued right now?

By the GLS models, yes: at 2.10 the stock is 83% below the average fair value of 12.11 (data as of 16 Oct 2026). Whether the discount is deserved is the question to research next.

What is the Wheel Score of XAIR and what does it mean?

XAIR has no listed options in our nightly snapshot, so it cannot be wheeled; its Wheel Score is capped at 39 and shown as "No options".

What is the GLS fair value for XAIR?

12.11 per share as of 16 Oct 2026 - the simple average of the 1 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.

When does Beyond Air, Inc. report earnings next?

The next earnings report is due on 10 Nov 2026, 25 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.

Does XAIR have listed options, and how liquid are they?

No. The nightly options snapshot found no listed contracts on XAIR, so the wheel strategy cannot be run on it and the Wheel Score is capped at 39.

Data as of 16 Oct 2026: prices and fundamentals from Financial Modeling Prep, option data from Polygon; valuations, scores and the Wheel Score by GLS Equity's models, run nightly. Prices in USD; the close shown is the previous session's. Everything on this page is general information produced by automated models from third-party data - not a recommendation to buy, sell or trade any security or option, and not financial advice. Past performance is not indicative of future results. GLS Equity provides data and tools, not financial advice.